Overview

A Study of GANFORT® UD in Patients With Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT) in a Medical Setting

Status:
Completed
Trial end date:
2014-12-19
Target enrollment:
Participant gender:
Summary
The study will evaluate patients diagnosed with POAG or OHT who are switched to GANFORT® UD (unit dose of fixed combination bimatoprost and timolol) therapy for medical reasons in accordance with physician standard clinical practice. All treatment decisions lie with the physician.
Details
Lead Sponsor:
Allergan
Treatments:
Bimatoprost
Cloprostenol
Timolol